ArticleCritical care (London, England)2023
Human cytomegalovirus seropositivity is associated with reduced patient survival during sepsis.
Article in Critical care (London, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 23 citations in OpenAlex.
- Viral Reactivation in Immunocompetent Critically Ill Patients.Microorganisms · 2026Review
- Human Cytomegalovirus Serostatus Defines Cytokine-Based Predictive Signatures in Sepsis.Pathogens (Basel, Switzerland) · 2026Observational
- Risk stratification for CMV reactivation in sepsis patients: development of an interpretable machine learning model.BMC infectious diseases · 2025Article
- Machine learning identifies clinical sepsis phenotypes that translate to the plasma proteome.Infection · 2025Article
- Plasma proteomics identifies molecular subtypes in sepsis.Critical care (London, England) · 2025Article
- Detection of cytomegalovirus in the lower respiratory tract among patients with critical illness: uncovering enhanced potential benefits.Critical care (London, England) · 2025Article
- Article
- Active cytomegalovirus infection in mechanically ventilated patients with sepsis.BMC infectious diseases · 2024Article
- Cytokine levels in breast cancer are highly dependent on cytomegalovirus (CMV) status.Breast cancer research and treatment · 2024Article
- Cytomegalovirus end-organ disease in immunocompromised critically ill patients: key concerns demanding attention.Critical care (London, England) · 2024Article
- High expression of L-GILZ transcript variant 1 (GILZ TV 1) is associated with increased 30-day sepsis mortality, and a high expression ratio possibly contraindicates hydrocortisone administration.Critical care (London, England) · 2024Article
- Comment to "Human cytomegalovirus seropositivity is associated with reduced patient survival during sepsis".Critical care (London, England) · 2024Article
- The Impact of Pathogens on Sepsis Prevalence and Outcome.Pathogens (Basel, Switzerland) · 2024Review
- Methazolamide Reduces the AQP5 mRNA Expression and Immune Cell Migration-A New Potential Drug in Sepsis Therapy?International journal of molecular sciences · 2024Article
- Exploring the relationship between HCMV serostatus and outcomes in COVID-19 sepsis.Frontiers in immunology · 2024Observational
- Response to comment on human cytomegalovirus seropositivity is associated with reduced patient survival during sepsis.Critical care (London, England) · 2023Article
- Comment on human cytomegalovirus seropositivity is associated with reduced patient survival during sepsis.Critical care (London, England) · 2023Article
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
36 authors at 10 institutions in 1 country.
Funding
Abstract
backgroundSepsis is one of the leading causes of death. Treatment attempts targeting the immune response regularly fail in clinical trials. As HCMV latency can modulate the immune response and changes the immune cell composition, we hypothesized that HCMV serostatus affects mortality in sepsis patients.
methodsWe determined the HCMV serostatus (i.e., latency) of 410 prospectively enrolled patients of the multicenter SepsisDataNet.NRW study. Patients were recruited according to the SEPSIS-3 criteria and clinical data were recorded in an observational approach. We quantified 13 cytokines at Days 1, 4, and 8 after enrollment. Proteomics data were analyzed from the plasma samples of 171 patients.
resultsThe 30-day mortality was higher in HCMV-seropositive patients than in seronegative sepsis patients (38% vs. 25%, respectively; p = 0.008; HR, 1.656; 95% CI 1.135-2.417). This effect was observed independent of age (p = 0.010; HR, 1.673; 95% CI 1.131-2.477). The predictive value on the outcome of the increased concentrations of IL-6 was present only in the seropositive cohort (30-day mortality, 63% vs. 24%; HR 3.250; 95% CI 2.075-5.090; p < 0.001) with no significant differences in serum concentrations of IL-6 between the two groups. Procalcitonin and IL-10 exhibited the same behavior and were predictive of the outcome only in HCMV-seropositive patients.
conclusionWe suggest that the predictive value of inflammation-associated biomarkers should be re-evaluated with regard to the HCMV serostatus. Targeting HCMV latency might open a new approach to selecting suitable patients for individualized treatment in sepsis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.